CORPORATE ACTION:

2024 Unit rights issue

DIGITAL THERAPEUTICS FOR ALZHEIMER’S DISEASE AND DEMENTIA

Our mission is to restore patients’ independence and quality of life by treating cognitive decline in Dementia with digital technology

Senior couple embracing

DEMENTIA IS PROJECTED TO BECOME A LEADING CAUSE OF DEATH AND HEALTHCARE COSTS

Brain+ is addressing one of the largest healthcare challenges of our time, namely dementia. Currently, A new case of dementia arises somewhere in the world every 3 seconds and globally an estimated 55 million people are living with dementia – and unfortunately, this figure is expected to almost triple to 139 million people by 2050. As we generally live longer and the prevention and treatment of the most common causes of death such as cancer and heart disease are getting more efficient, dementia is expected to become a leading cause of death by 2030 and is already the leading cause of death for women in the UK.

Dementia puts an enormous emotional burden on the patients and their loved ones as cognitive abilities deteriorate, behaviours change, and independence is lost. It is also a massive and increasing financial burden on society and our health care systems with an accumulated global cost upwards of 1 trillion USD globally today and expected to double to 2 trillion USD within decades, and eventually expected to eclipse the cost of cancer and heart disease.

TREATING DEMENTIA WITH DIGITAL THERAPEUTICS

Despite massive investments in research for treatments of dementia, there is still a high need for innovative and effective treatments for dementia.

The good news is that Brain+ is leveraging new and innovative methods to create groundbreaking new treatments and provide these to patients through digital therapeutics.

So far, initial trials indicate positive effects of these new methods for treating cognitive decline in dementia.

WHAT ARE DIGITAL THERAPEUTICS?

“Digital Therapeutics” is a term for digital treatments that deliver scientifically validated positive outcomes for a wide range of diseases, and often for the same medical endpoints as classical drugs.

In this sense, DTX offers a new and rapidly growing approach to the way healthcare systems identify and treat diseases and could offer new solutions in areas with large unmet clinical needs.

DTx delivers treatments in purely digital formats, like software and apps, on people’s smart devices. These treatments can have health effects similar to traditional, chemically-based medicine. DTx products undergo clinical trials and collect real-world evidence to establish clinical relevance and are reviewed and cleared or certified by regulatory bodies as required to support risk, efficacy, product claims and intended use. This allows for new and unique treatment opportunities that can be used either as a complementary treatment to classic medicine or as a standalone solution in areas where traditional drugs do not offer a solution.

Holding hands

Cognitive Stimulation Therapy (CST)
for treatment of Dementia

In 2020, Brain+ partnered with researchers and clinicians in Denmark to digitalize an evidenced based manual therapy, CST, targeting people with mild to moderate dementia.

Cognitive Stimulation Therapy uses psychosocial interaction to stimulate cognition and create new associations via existing memories, stimulation of memory networks, imagination for people with mild to moderate Alzheimer’s. It also works to increase the quality of the patient’s interaction with their caregivers, as it facilitates a structured way to engage socially. It provides orientation to make the participants feel safe and self-confident, stimulating cognition through multiple sensory activation, and using reminiscence as an aid to the here-and-now.

The first Brain+ digitalized CST product is designed for use in clinics. The second Brain+ product, currently in R&D, is designed to continue CST at home.

Read more about CST here

Holding hands

PRODUCTS

Your digital CST Assistant

The digital CST assistant gives you access to 24 prepared Cognitive Stimulation Therapy sessions (CST), ready for use in a CST group setting.

The digital CST assistant creates the foundation for meaningful conversations based on the evidence-based group therapeutic method of CST.

The Digital CST assistant is currently available in Danish. More language versions to follow.

NEWS

SCIENCE

Expanding our knowledge of the brain

Research Pipeline

Therapeutic Area

Stage

Partners

Project

Healthy elderlies. Mild cognitive impairment (MCI)

Phase 2, Proof of Concept

Alzheimer’s Disease Detect & Prevent

Healthy elderlies. Preclinical Alzheimer’s disease (PAD)

Phase 2, Proof of Concept

Alzheimer’s Disease Detect & Prevent

Subjective cognitive impairments (SCI)

Phase 2, Proof of Concept

Alzheimer’s Disease Detect & Prevent

At risk of Alzheimer’s Disease (aRoA)

Phase 2, Proof of Concept

ACT TDCS

Early Dementia (ED)

Phase 2, Proof of Concept

CST Brain+ Project

Mild cognitive impairments (MCI)

Phase 2, Proof of Concept

Alzheimer’s Disease Shield

Latest: August 2021  |  Pipeline is subject to change

Research Pipeline

Therapeutic Area:
Healthy elderlies. Mild cognitive impairment (MCI)

Stage:

Phase 2, Proof of Concept

Partners:

Project: Alzheimer’s Disease Detect & Prevent

Therapeutic Area:
Healthy elderlies. Preclinical Alzheimer’s disease (PAD)

Stage:

Phase 2, Proof of Concept

Partners:

Project: Alzheimer’s Disease Detect & Prevent

Therapeutic Area:
Subjective cognitive impairments (SCI)

Stage:

Phase 2, Proof of Concept

Partners:

Project: Alzheimer’s Disease Detect & Prevent

Therapeutic Area:
At risk of Alzheimer’s Disease (aRoA)

Stage:

Phase 2, Proof of Concept

Partners:

Project: ACT TDCS

Therapeutic Area:
Early Dementia (ED)

Stage:

Phase 2, Proof of Concept

Partners:

Project: CST Brain+ Project

Therapeutic Area:
Mild cognitive impairments (MCI)

Stage:

Phase 2, Proof of Concept

Partners:

Project: Alzheimer’s Disease Shield

STAY INFORMED

Be the first to receive company updates, press releases and news.